Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Heron Therapeutics, Inc. (HRTX) had Debt to Capital Ratio of 0.95 for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$37.67M |
|
$-5.49M |
|
$11.57M |
|
$26.09M |
|
$39.71M |
|
$-2.04M |
|
$-3.44M |
|
$-5.49M |
|
$-5.49M |
|
$-5.49M |
|
$-5.49M |
|
$-5.49M |
|
$-5.49M |
|
$-2.04M |
|
$-1.52M |
|
190.34M |
|
190.34M |
|
$-0.03 |
|
$-0.03 |
|
| Balance Sheet Financials | |
$229.84M |
|
$11.81M |
|
$22.42M |
|
$252.26M |
|
$92.14M |
|
$142.65M |
|
$153.21M |
|
$245.35M |
|
$5.86M |
|
$6.91M |
|
$6.91M |
|
189.46M |
|
| Cash Flow Statement Financials | |
$-3.75M |
|
$-4.20M |
|
$0.03M |
|
$28.65M |
|
$20.72M |
|
$-7.93M |
|
$6.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.49 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.95 |
20.65 |
|
69.28% |
|
-5.43% |
|
-5.43% |
|
-- |
|
-14.57% |
|
-14.57% |
|
$-4.28M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
0.13 |
|
0.42 |
|
214.02 |
|
-93.70% |
|
-79.46% |
|
-2.18% |
|
-3.67% |
|
$0.04 |
|
$-0.02 |
|
$-0.02 |
|